rs11937537 - RPS23P3 - RNU6-699P

Magnitude 2.2 · 1 study on file

Reported associations

• Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate - Unknown journal (n.d.) · Unknown authors · PubMed 35671649

  ABSTRACT: Objective: To examine genetic influence on the risk of elevations in liver function tests (AST and ALT) among patients using low-dose methotrexate (LD-MTX). Methods: We examined data from the LD-MTX arm of a randomized double-blind placebo-controlled trial conducted among subjects without rheumatic disease. Genome wide association studies (GWAS) were performed in subjects of European ancestry to test the association between single nucleotide polymorphisms (SNPs) and the log transformed maximum values of AST, ALT, and dichotomized outcome with AST or ALT > 2 times upper limit of normal (ULN). The association between variants in MTX metabolism candidate genes and the outcomes was also tested. Furthermore, associations between a drug induced liver injury (DILI) weighted genetic risk

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.